title: Treatment of a major depression episode suppresses markers of bone turnover in premenopausal women.
abstract: Both decrease in bone mineral density and increase in bone turnover had been reported in patients with major depression compared to healthy controls. But the effect of antidepressant treatment on markers of bone turnover is not studied. The aim of this study was to investigate the effect of treatment of a major depressive episode with an SSRI antidepressant on bone turnover in premenopausal women.
  
  
  METHODS
  Fifty premenopausal female patients with newly diagnosed major depression according to DSM IV-R criteria were included into the study. Before starting antidepressant therapy (escitalopram 10 mg/day) and three months later, blood samples were collected for the measurement of serum calcium, phosphorus, osteocalcin, β-CTX and iPTH. Depressive status was determined with Hamilton Depression Scale.
  
  
  RESULTS
  Treatment of depression did not create any change in laboratory levels of either calcium or phosphorus. Basal iPTH level was significantly decreased with the treatment. Treatment resulted in an increase in serum osteocalcin and decrease in β-CTX levels. HAMD score was significantly correlated with both osteocalcin and β-CTX. The decrease in β-CTX and increase in osteocalcin levels were more prominent in patients with a HAMD score that remained below 15 than above 15 at the end of the study period. In conclusion, this study shows that with the treatment of depression bone formation increases and bone resorption decreases in premenopausal women with major depression.
authors.affiliation: Yeditepe University, Department of Internal Medicine, Section of Endocrinology and Metabolism, Yeditepe Universitesi Hastanesi, Devlet Yolu Ankara Cad. Kozyatagi, Istanbul, Turkey. haydin@yeditepe.edu.tr
authors.forename: Hasan
authors.initials: H
authors.lastname: Aydin
authors.forename: Nilgun
authors.initials: N
authors.lastname: Mutlu
authors.forename: Naz Berfu Gunel
authors.initials: NB
authors.lastname: Akbas
mesh_terms: D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D001862:Bone Resorption / Q000097:blood* / Q000188:drug therapy; D002118:Calcium / Q000097:blood; D002922:Ciguatoxins / Q000097:blood; D015283:Citalopram / Q000008:administration & dosage / Q000494:pharmacology; D003865:Major Depressive Disorder / Q000097:blood* / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis / Q000187:drug effects*; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D017697:Premenopause / Q000097:blood* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D016896:Treatment Outcome; D014930:Women / Q000523:psychology; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D015415:Biomarkers; D002118:Calcium; D002922:Ciguatoxins; D015283:Citalopram; D015675:Osteocalcin; D010281:Parathyroid Hormone; D010758:Phosphorus; D017367:Selective Serotonin Reuptake Inhibitors